PDF(Sci-hub)
Abstract：
BACKGROUND: Zika virus (ZIKV) is transmitted to humans throughout bites of Aedes mosquitoes. ZIKV infection may be asymptomatic in most cases, but it may cause fever, headache, muscle pain, and rash. Guillain-Barré syndrome also may be associated with the infection. Furthermore, the Pan American Health Organization informed 3,715 cases of the congenital ZIKV syndrome (CZS) in the Americas from 2015 - 2017, which may include microcephaly and other craniofacial deformities.
UNASSIGNED: This review identifies patent documents on repositioning for ZIKV infection treatment of already approved drugs or phases II/III investigated drugs for other diseases. Thirty-six patents were found reporting compounds with anti-ZIKV activity with application dates ranging from 2015 to 2019.
UNASSIGNED: The main drugs claimed in patents were ribavirin, sofosbuvir, and alpha interferons. Preventing CZS is one of the most significant challenges in ZIKV infection. Therefore, repositioning sofosbuvir and niclosamide, that pose no danger for pregnant women, is a particular issue to be considered for clinical tests involving ZIKV disease. Given the substantial costs and developing time of new a drug, repositioning of old drugs is becoming an attractive alternative for diseases with neglected treatments.
UNASSIGNED: This review identifies patent documents on repositioning for ZIKV infection treatment of already approved drugs or phases II/III investigated drugs for other diseases. Thirty-six patents were found reporting compounds with anti-ZIKV activity with application dates ranging from 2015 to 2019.
UNASSIGNED: The main drugs claimed in patents were ribavirin, sofosbuvir, and alpha interferons. Preventing CZS is one of the most significant challenges in ZIKV infection. Therefore, repositioning sofosbuvir and niclosamide, that pose no danger for pregnant women, is a particular issue to be considered for clinical tests involving ZIKV disease. Given the substantial costs and developing time of new a drug, repositioning of old drugs is becoming an attractive alternative for diseases with neglected treatments.
摘要：
背景：寨卡病毒（ZIKV）通过伊蚊叮咬传播给人类。ZIKV感染在大多数情况下可能是无症状的，但它可能会导致发烧，头痛,肌肉疼痛，和皮疹。格林-巴利综合征也可能与感染有关。此外，泛美卫生组织通报了2015-2017年美洲3,715例先天性ZIKV综合征(CZS)病例,其中可能包括小头畸形和其他颅面畸形.
■本审查确定了关于重新定位ZIKV感染治疗已经批准的药物或II/III期其他疾病研究药物的专利文件。发现36项专利报告了具有抗ZIKV活性的化合物，申请日期为2015年至2019年。
■专利中声称的主要药物是利巴韦林，sofosbuvir,和α干扰素。预防CZS是ZIKV感染中最重要的挑战之一。因此,重新定位索非布韦和氯硝柳胺，对孕妇没有危险，是涉及ZIKV疾病的临床试验需要考虑的特殊问题。考虑到新药的巨大成本和开发时间，旧药物的重新定位正在成为被忽视治疗的疾病的一种有吸引力的替代方案。
■本审查确定了关于重新定位ZIKV感染治疗已经批准的药物或II/III期其他疾病研究药物的专利文件。发现36项专利报告了具有抗ZIKV活性的化合物，申请日期为2015年至2019年。
■专利中声称的主要药物是利巴韦林，sofosbuvir,和α干扰素。预防CZS是ZIKV感染中最重要的挑战之一。因此,重新定位索非布韦和氯硝柳胺，对孕妇没有危险，是涉及ZIKV疾病的临床试验需要考虑的特殊问题。考虑到新药的巨大成本和开发时间，旧药物的重新定位正在成为被忽视治疗的疾病的一种有吸引力的替代方案。
